Login to Your Account



Pharma: Clinic Roundup


Thursday, May 30, 2013
• Eli Lilly and Co., of Indianapolis, reported new data showing that Forteo significantly increased lumbar spine volumetric bone mineral density (vBMD) compared to risedronate in men with glucocorticoid-induced osteoporosis.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription